Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.